SZC may be a promising therapeutic tool to improve hyperkalemia, allowing up-titration of renin–angiotensin–aldosterone system inhibitors and facilitating cardiac reverse remodeling in patients with heart failure with LVEF <50% and hyperkalemia. The gene discussed is REN; the disease is Hyperkalemia.